These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 26590814)

  • 1. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.
    Wolfe AR; Debeb BG; Lacerda L; Larson R; Bambhroliya A; Huang X; Bertucci F; Finetti P; Birnbaum D; Van Laere S; Diagaradjan P; Ruffell B; Trenton NJ; Chu K; Hittelman W; Diehl M; Levental I; Ueno NT; Woodward WA
    Breast Cancer Res Treat; 2015 Dec; 154(3):495-508. PubMed ID: 26590814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO3a expression is associated with lymph node metastasis and poor disease-free survival in triple-negative breast cancer.
    Rehman A; Kim Y; Kim H; Sim J; Ahn H; Chung MS; Shin SJ; Jang K
    J Clin Pathol; 2018 Sep; 71(9):806-813. PubMed ID: 29588373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simvastatin promotes cardiac microvascular endothelial cells proliferation, migration and survival by phosphorylation of p70 S6K and FoxO3a.
    Pan Q; Xie X; Guo Y; Wang H
    Cell Biol Int; 2014 May; 38(5):599-609. PubMed ID: 24375611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCN5/WISP-2 promotes growth arrest of triple-negative breast cancer cells through accumulation and trafficking of p27(Kip1) via Skp2 and FOXO3a regulation.
    Haque I; Banerjee S; De A; Maity G; Sarkar S; Majumdar M; Jha SS; McGragor D; Banerjee SK
    Oncogene; 2015 Jun; 34(24):3152-63. PubMed ID: 25132260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simvastatin suppresses osteoblastic expression of Cyr61 and progression of apical periodontitis through enhancement of the transcription factor Forkhead/winged helix box protein O3a.
    Lin LD; Lin SK; Chao YL; Kok SH; Hong CY; Hou KL; Lai EH; Yang H; Lee MS; Wang JS
    J Endod; 2013 May; 39(5):619-25. PubMed ID: 23611379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simvastatin inhibits cysteine-rich protein 61 expression in rheumatoid arthritis synovial fibroblasts through the regulation of sirtuin-1/FoxO3a signaling.
    Kok SH; Lin LD; Hou KL; Hong CY; Chang CC; Hsiao M; Wang JH; Lai EH; Lin SK
    Arthritis Rheum; 2013 Mar; 65(3):639-49. PubMed ID: 23239110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency.
    Jung HH; Lee SH; Kim JY; Ahn JS; Park YH; Im YH
    Sci Rep; 2016 Sep; 6():33035. PubMed ID: 27604655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of KIF3A inhibits triple negative breast cancer growth and metastasis by repressing Rb-E2F signaling and epithelial-mesenchymal transition.
    Wang W; Zhang R; Wang X; Wang N; Zhao J; Wei Z; Xiang F; Wang C
    Cancer Sci; 2020 Apr; 111(4):1422-1434. PubMed ID: 32011034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forkhead Box Transcription Factor (FOXO3a) mediates the cytotoxic effect of vernodalin in vitro and inhibits the breast tumor growth in vivo.
    Ananda Sadagopan SK; Mohebali N; Looi CY; Hasanpourghadi M; Pandurangan AK; Arya A; Karimian H; Mustafa MR
    J Exp Clin Cancer Res; 2015 Dec; 34():147. PubMed ID: 26643256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer.
    Chen J; Gomes AR; Monteiro LJ; Wong SY; Wu LH; Ng TT; Karadedou CT; Millour J; Ip YC; Cheung YN; Sunters A; Chan KY; Lam EW; Khoo US
    PLoS One; 2010 Aug; 5(8):e12293. PubMed ID: 20808831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
    Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
    Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyaluronic acid engrafted metformin loaded graphene oxide nanoparticle as CD44 targeted anti-cancer therapy for triple negative breast cancer.
    Basu A; Upadhyay P; Ghosh A; Bose A; Gupta P; Chattopadhyay S; Chattopadhyay D; Adhikary A
    Biochim Biophys Acta Gen Subj; 2021 Mar; 1865(3):129841. PubMed ID: 33412224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic antitumor effect of NVP-BEZ235 and CAPE on MDA-MB-231 breast cancer cells.
    Torki S; Soltani A; Shirzad H; Esmaeil N; Ghatrehsamani M
    Biomed Pharmacother; 2017 Aug; 92():39-45. PubMed ID: 28528184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCN1, a candidate target for zoledronic acid treatment in breast cancer.
    Espinoza I; Liu H; Busby R; Lupu R
    Mol Cancer Ther; 2011 May; 10(5):732-41. PubMed ID: 21393426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
    Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
    BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer.
    Gagliardi M; Pitner MK; Park J; Xie X; Saso H; Larson RA; Sammons RM; Chen H; Wei C; Masuda H; Chauhan G; Kondo K; Tripathy D; Ueno NT; Dalby KN; Debeb BG; Bartholomeusz C
    Sci Rep; 2020 May; 10(1):8537. PubMed ID: 32444778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.